Sertraline

Generic Name
Sertraline
Brand Names
Zoloft
Drug Type
Small Molecule
Chemical Formula
C17H17Cl2N
CAS Number
79617-96-2
Unique Ingredient Identifier
QUC7NX6WMB
Background

Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...

Indication

Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...

Associated Conditions
Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
Associated Therapies
-
Clinical Trials
Related News

PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

First Posted Date
2015-08-13
Last Posted Date
2018-04-10
Lead Sponsor
University of Utah
Target Recruit Count
5
Registration Number
NCT02520726
Locations
🇺🇸

University of Utah Hospital, Salt Lake City, Utah, United States

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

Phase 4
Completed
Conditions
PTSD
Alcohol Use Disorder
Interventions
Drug: Placebo
Drug: Sertraline
First Posted Date
2015-07-22
Last Posted Date
2018-04-10
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
49
Registration Number
NCT02504931
Locations
🇺🇸

South Texas Veterans Health Care System, San Antonio, Texas, United States

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

First Posted Date
2015-06-11
Last Posted Date
2018-09-07
Lead Sponsor
Medical University of Bialystok
Target Recruit Count
60
Registration Number
NCT02469545
Locations
🇵🇱

Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland

Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

First Posted Date
2015-06-04
Last Posted Date
2016-05-03
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
2
Registration Number
NCT02463110
Locations
🇫🇷

ACTION Group - Pitié-Salpêtrière University Hospital (APHP), Paris, France

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

First Posted Date
2015-05-25
Last Posted Date
2022-06-02
Lead Sponsor
Gustavo Rivero
Target Recruit Count
14
Registration Number
NCT02452983
Locations
🇺🇸

Michael E. DeBakey VA Medical Center, Houston, Texas, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

A Trial of Sertraline in Young Children With Autism Spectrum Disorder

First Posted Date
2015-03-11
Last Posted Date
2019-10-22
Lead Sponsor
Randi J. Hagerman, MD
Target Recruit Count
58
Registration Number
NCT02385799
Locations
🇺🇸

UC Davis MIND Institute, Sacramento, California, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety

First Posted Date
2015-01-27
Last Posted Date
2016-07-11
Lead Sponsor
University College, London
Target Recruit Count
5
Registration Number
NCT02347033
Locations
🇬🇧

Camden & Islington (with Kingston), London, United Kingdom

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

First Posted Date
2014-12-19
Last Posted Date
2016-03-14
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
3255526
Registration Number
NCT02320240
Locations
🇨🇦

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)

First Posted Date
2014-10-21
Last Posted Date
2019-05-24
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
10
Registration Number
NCT02269540
Locations
🇨🇦

Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy